Psilocybin PTSD Legislation Tracker: State-by-State Status (2026)

Psilocybin legislation for PTSD is moving faster than most national coverage reflects. Conservative states with high veteran populations are leading the charge — Iowa, South Dakota, Missouri, Texas — in one of the few genuinely bipartisan policy areas in 2026. This tracker covers every active bill, its current status, and what it would actually do for patients.

Last updated: March 25, 2026. Check back — this page updates as bills advance.

Quick Status Summary

State	Bill	Status	Would Do
South Dakota	HB 1099	Signed into law (Mar 10, 2026)	Trigger law — legalizes psilocybin as prescription upon FDA approval
Iowa	HF 978	Awaiting Senate floor vote	PTSD-only regulated access program
Missouri	HB 1717 + HB 1643	Committee passed, floor pending	Veteran PTSD access + broader adult access
Texas	SB 2308	Signed into law (Jun 2025)	$50M ibogaine/psilocybin research consortium
New Jersey	S. 2283	Signed into law (Jan 20, 2026)	$6M hospital-based psilocybin research pilot
Virginia	HB 1347	Advancing	Trigger law — prescriptions upon FDA approval/DEA rescheduling
Oklahoma	HB 3834	Passed committee (Mar 2026)	Ibogaine clinical trial consortium
California	AB 1103	Signed into law (Oct 2025)	Accelerates psychedelic research for PTSD, depression, addiction
Federal	H.R. 72 / Senate companion	Pending	VA centers of excellence for psychedelic therapy

Signed Into Law

South Dakota HB 1099 — Signed March 10, 2026

What it does: A trigger law that automatically reclassifies synthesized psilocybin from Schedule I to Schedule IV upon FDA approval and DEA rescheduling — instantly legalizing it as a prescription medication in South Dakota for therapeutic settings. Recreational use remains illegal.

Legislative history: Passed House 58-7 (Feb 9), Senate Health and Human Services Committee 6-0 (Feb 25), passed Senate 21-12 (March 2), signed by Governor Larry Rhoden (R) on March 10, 2026.

Key supporters: COMPASS Pathways testified in support. VETS (Veterans Exploring Treatment Solutions) emphasized that more than 125,000 veterans have died by suicide since 2001.

Practical limitation: Does nothing until the federal government approves psilocybin. Similar trigger laws have been adopted in North Dakota, Nebraska, Arizona, and Colorado (HB 25-1063).

Source: South Dakota Searchlight, March 10, 2026

Texas SB 2308 — Signed June 2025

What it does: Appropriates $50 million for an ibogaine clinical trial consortium targeting opioid use disorder, PTSD, and neurological conditions — the largest state-funded psychedelic research initiative in U.S. history. A separate 2021 law (HB 1802) already funded the first state-sponsored psilocybin research for veterans with PTSD, led by Baylor University and the Menninger Clinic.

Source: KUT, June 2025

New Jersey S. 2283 — Signed January 20, 2026

What it does: Provides $6 million for hospital-based psilocybin research at three hospitals ($2 million each) and creates a Psychedelic Therapy and Research Advisory Board.

Source: Reason Foundation, March 2026

California AB 1103 — Signed October 2025

What it does: Accelerates psychedelic research for PTSD, depression, and addiction. Effective January 1, 2026 through January 1, 2028. Backed by veteran advocacy organizations.

Source: Military.com, October 2025

Active — Awaiting Vote

Iowa HF 978 — Awaiting Senate Floor Vote

Current status: Passed Iowa House 84-6 in April 2025. Passed Senate Health and Human Services Committee (voice vote) on March 19, 2026. Survived Iowa's second funnel deadline on March 20, 2026. Now eligible for a full Senate floor vote — no vote scheduled as of March 25, 2026.

What it would do: Create a state-regulated psilocybin therapy program specifically for PTSD patients. Adults 21+ with a medical professional recommendation could access psilocybin produced in-state by licensed entities. Administration sessions supervised by registered facilitators, conducted at registered clinical locations, and video recorded. License applications would begin July 1, 2026 if enacted.

Key details:

Narrowed to PTSD-only by Senate committee amendment (House version was broader)
Oversight shifted to existing Medical Cannabidiol Advisory Board (renamed)
Licensed psilocybin production facilities could co-locate with licensed medical cannabis producers
Local governments cannot ban psilocybin facilities
HHS directed to study "use of psychedelic compounds other than psilocybin in the treatment of medical conditions"

Governor risk: Governor Kim Reynolds (R) vetoed a separate psilocybin bill (HF 383) in June 2025, saying it "surrenders state authority to federal officials." HF 978 is specifically designed to address her concerns with an Iowa-centric regulatory approach.

Sponsor: Rep. John Wills (R-Spirit Lake), 25-year Iowa National Guard veteran. Backed by VETS.

Sources: Iowa Capital Dispatch, March 18-19, 2026; Iowa Public Radio, March 20, 2026; Marijuana Moment, March 19, 2026

Missouri HB 1717 + HB 1643 — Committee Passed, Floor Pending

Current status: House Emerging Issues Committee passed a combined proposal on February 16, 2026, merging HB 1717 and HB 1643 with two ibogaine bills (HB 2817, HB 2961). Final merged bill text not yet published as of March 25, 2026.

HB 1717 — Veterans Focus: Would allow military veterans 21+ diagnosed with PTSD, major depressive disorder, substance use disorder, or end-of-life needs to access psilocybin while enrolled in a psilocybin study. Requires advance notice to the Missouri Department of Mental Health and supervised use with a qualified facilitator. Includes $2 million in state research grants and a 150mg annual psilocybin analyte cap. Sponsor: Rep. Richard West (R-District 102).

HB 1643 — Broader Access: Would extend similar access to any adult 21+ with qualifying conditions (PTSD, major depression, substance use disorder, end-of-life care, or any condition with FDA clinical trial evidence) — not limited to veterans, not requiring study enrollment. Also revises Missouri's right-to-try statute to include Schedule I substances. Sponsor: Rep. Matthew Overcast (R-District 155).

Sources: Marijuana Moment, February 2026; DoubleBlind, March 2026; Reason Foundation, March 2026

Virginia HB 1347 — Advancing

What it would do: Direct the Board of Pharmacy to issue regulations for prescribing psilocybin upon FDA approval and DEA rescheduling. A trigger-style bill that prepares Virginia's prescription infrastructure for federal approval.

Current status: Engrossed during second reading February 10, 2026. A prior version (SB 1135) was vetoed by the governor in 2025.

Source: Reason Foundation, March 2026

Oklahoma HB 3834 — Passed Committee March 2026

What it would do: Create an ibogaine clinical trial consortium targeting FDA approval — the "Oklahoma Breakthrough Therapy Act."

Current status: Passed House committee with a "Do Pass" recommendation in February 2026. Passed out of the Oklahoma House of Representatives 68-23 in March 2026.

Source: Reason Foundation, March 2026; Americans for Ibogaine tracker

Federal Legislation

H.R. 72 — Innovative Therapies Centers of Excellence Act of 2025

What it would do: Require the VA to designate at least five facilities as centers of excellence for psychedelic therapy research. Bipartisan — sponsored by Reps. Correa (D) and Bergman (R).

Endorsements: American Legion, DAV, VFW, IAVA, Wounded Warrior Project.

Senate companion (March 2026): Senator Gallego introduced a companion bill providing $30 million annually for VA psychedelic centers of excellence.

VA action already underway: In November 2025, the VA expanded psychedelic therapy trials to nine facilities — Portland OR, Palo Alto, San Francisco, Los Angeles, Bronx, Omaha, San Diego, West Haven, White River Junction — the first VA-funded psychedelic research since the 1960s.

Source: Military.com, March 9, 2026

2024 National Defense Authorization Act

The 2024 NDAA directed the Department of Defense to fund clinical research on psychedelics for PTSD and traumatic brain injury. Implementation is ongoing.

Why Conservative States Are Leading

The pattern across Iowa, South Dakota, Missouri, Texas, and Oklahoma is consistent: Republican-sponsored bills, veteran-focused framing, and bipartisan floor votes. The driving coalition is veteran advocacy organizations — VETS, Heroic Hearts Project, American Legion, DAV — combined with lawmakers who have personal connections to veteran suicide or PTSD.

Iowa's primary sponsor served 25 years in the National Guard. South Dakota's bill was championed by veteran advocates citing 125,000+ veteran suicides since 2001. Texas's ibogaine program grew directly from a veteran mental health crisis.

This is not the psychedelic counterculture pushing these bills. It's veterans and the lawmakers who represent them.

What Passage Would Mean for Patients

If Iowa HF 978 passes and is signed: Iowa becomes the third state with a regulated psilocybin access program, the first specifically limited to PTSD patients. Access would begin after the licensing infrastructure is built — realistically late 2026 or 2027.

If South Dakota's trigger law activates (upon FDA approval): South Dakota residents could access psilocybin as a prescription medication without traveling to Oregon or Colorado.

If Missouri's combined bill passes: Veterans could access psilocybin therapy while enrolled in state-funded research, with broader adult access potentially following.

Today, without waiting: Oregon and Colorado already have operational programs. Any adult 21+ — no diagnosis required — can access psilocybin at a licensed service center. Browse licensed Oregon psilocybin service centers or Colorado healing centers. For a full breakdown of where psilocybin is legal, see our state-by-state guide.

Other States to Watch in 2026

New Hampshire HB 1809: Medical psilocybin through DHHS. Received "ought to pass" committee recommendation February 2026.
Utah SB 266 (enacted March 2024): Three-year pilot allowing University of Utah Health and Intermountain Health to administer psilocybin and MDMA therapeutically — already operational.
New York A. 3845: Psilocybin-assisted therapy pilot for up to 10,000 veterans and first responders. Awaiting hearing in Assembly Health Committee. Assessed as unlikely to pass this session.
Washington SB 5921: Would place a medical-use program under the Washington Department of Health. Advancing in 2026 session.

How This Connects to Federal Approval

Every state trigger law — South Dakota, North Dakota, Nebraska, Arizona, Virginia — is betting on federal approval. That bet has a concrete timeline: COMPASS Pathways plans to submit a rolling New Drug Application (NDA) for COMP360 psilocybin in Q4 2026, targeting FDA approval in late 2026 or early 2027. If approved, COMP360 would become the first classic psychedelic cleared for the U.S. market.

For a full breakdown of the federal approval pipeline, see our Psilocybin FDA Approval Status Tracker.

Psilocybin remains a Schedule I controlled substance under federal law. This tracker is for informational purposes only and does not constitute legal or medical advice. State laws change frequently — verify current status before making any decisions. Last updated March 25, 2026.